Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world's most devastating diseases. The first vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Guerin (BCG) as a prevention against TB. BCG protects against disseminated disease...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hopkins, R, Bridgeman, A, Joseph, J, Gilbert, S, McShane, H, Hanke, T
Format:	Journal article
Idioma:	English
Publicat:	Public Library of Science 2011

Ítems similars

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
per: Richard Hopkins, et al.
Publicat: (2011-01-01)

Vaccine strategies against tuberculosis
per: H McShane
Publicat: (2009-03-01)

Vaccines for tuberculosis
per: McShane, H
Publicat: (2013)

Vaccine Platform for Prevention of Mother-to-Child Transmission of HIV-1 through Breastfeeding
per: Im, E, et al.
Publicat: (2008)

Insights and challenges in tuberculosis vaccine development
per: McShane, H
Publicat: (2019)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
per: McShane, H
Publicat: (2011)

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin
per: McShane, H
Publicat: (2011)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
per: Christopher J. De Voss, et al.
Publicat: (2025-02-01)

Vaccination against tuberculosis: how can we better BCG?
per: Pitt, J, et al.
Publicat: (2013)

Vaccination against tuberculosis: How can we better BCG?
per: Pitt, J, et al.
Publicat: (2013)

Tuberculosis vaccines: Progress and challenges
per: Checkley, A, et al.
Publicat: (2011)

Vaccine strategies against tuberculosis.
per: Mcshane, H
Publicat: (2009)

Developing an improved vaccine against tuberculosis.
per: Mcshane, H
Publicat: (2004)

Improving tuberculosis vaccine trial efficiency: a tough nut to crack
per: McShane, H
Publicat: (2023)

Why don’t we have an effective tuberculosis vaccine yet?
per: Davenne, T, et al.
Publicat: (2016)

Clinical testing of tuberculosis vaccine candidates
per: Hatherill, M, et al.
Publicat: (2016)

The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
per: Vermaak, S, et al.
Publicat: (2023)

Replacing, reducing and refining the use of animals in tuberculosis vaccine 1 research
per: Tanner, R, et al.
Publicat: (2016)

WHO preferred product characteristics for new vaccines against tuberculosis
per: Schrager, L, et al.
Publicat: (2018)

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
per: Im, E, et al.
Publicat: (2007)

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
per: Dockrell, HM, et al.
Publicat: (2022)

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
per: Griffiths, K, et al.
Publicat: (2013)

Construction and characterization of recombinant MTBVAC. HIV, a new live attenuated vaccine against HIV and tuberculosis
per: Saubi, N, et al.
Publicat: (2018)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
per: Hazel M. Dockrell, et al.
Publicat: (2022-05-01)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
per: Villarreal-Ramos, B, et al.
Publicat: (2017)

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.
per: Sander, C, et al.
Publicat: (2007)

Human and Bovine Tuberculosis
per: McShane, H
Publicat: (2016)

MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice
per: Broset, E, et al.
Publicat: (2019)

Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
per: Bridgeman, A, et al.
Publicat: (2009)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
per: Esther Broset, et al.
Publicat: (2019-06-01)

Identification of antigens presented by MHC for vaccines against tuberculosis
per: Bettencourt, P, et al.
Publicat: (2020)

Identification of antigens presented by MHC for vaccines against tuberculosis
per: Bettencourt, P, et al.
Publicat: (2020)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
per: Stylianou, E, et al.
Publicat: (2019)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
per: Dean, G, et al.
Publicat: (2014)

MVA as a vector for vaccines against HIV-1.
per: Im, E, et al.
Publicat: (2004)

Engineering a dual vaccine against COVID-19 and tuberculosis
per: Carlyn Monèt Guthrie, et al.
Publicat: (2023-10-01)

Controlled human infection models: is it really feasible to give people tuberculosis?
per: McShane, H
Publicat: (2020)

Local pulmonary immunological biomarkers in tuberculosis
per: Morrison, H, et al.
Publicat: (2021)

Local Pulmonary Immunological Biomarkers in Tuberculosis
per: Hazel Morrison, et al.
Publicat: (2021-03-01)

Tuberculosis vaccines in clinical trials.
per: Rowland, R, et al.
Publicat: (2011)